decisions by regulatory authorities impacting labeling, manufacturing processes, safety, and/or other matters that could affect the availability or commercial potential of Pfizers oral GIPR antagonist candidate, other earlier obesity programs or any such other product candidates
Aging, obesity, metabolic stress, and genetic perturbations disrupt these regulatory networks, leading to redox imbalance, impaired oxidative phosphorylation, altered mitochondrial dynamics, and mitochondrial DNA instability
We hypothesise that many aspects of the weaponization programme detailed here will be common to the genesis of other plant-parasitic nematode effectors
The biopharma industry has over 60,000 job vacancies, 5 and skill development in this industry takes years